EP0980273A1 - Implant biodegradable d'osteosynthese - Google Patents

Implant biodegradable d'osteosynthese

Info

Publication number
EP0980273A1
EP0980273A1 EP98910571A EP98910571A EP0980273A1 EP 0980273 A1 EP0980273 A1 EP 0980273A1 EP 98910571 A EP98910571 A EP 98910571A EP 98910571 A EP98910571 A EP 98910571A EP 0980273 A1 EP0980273 A1 EP 0980273A1
Authority
EP
European Patent Office
Prior art keywords
implant
biodegradable
fracture
implant according
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910571A
Other languages
German (de)
English (en)
Inventor
Oskar E. Illi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
White Spot AG
Original Assignee
White Spot AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by White Spot AG filed Critical White Spot AG
Publication of EP0980273A1 publication Critical patent/EP0980273A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • the present invention relates to a biodegradable osteosynthesis implant according to the preamble of claim 1 or 2.
  • Metallic implants have been used in medicine to fix broken bones for over 200 years. Through the selection of suitable biocompatible metal alloys, the mechanical resilience and above all the tissue tolerance of these implants has been optimized in the past decades so that corrosion and rejection reactions hardly occur.
  • the metallic implants can lead to complications in the X-ray and tomographic diagnostic procedures.
  • their main disadvantage is that metallic implants cannot be left in the body indefinitely. After the fracture has healed, a second surgical procedure must be carried out to remove the implant. This not only brings a new burden on the patient, but also means considerable costs for the second surgical intervention and for a possible second stay of the patient in the hospital. In addition, there are direct and indirect follow-up costs due to loss of work and aftercare during the second wound healing.
  • implants made of resorbable polyester are far inferior in mechanical strength to the metal implants.
  • implants e.g. fiber-reinforced
  • suitable manufacturing processes e.g. injection molding
  • implants e.g. fiber-reinforced
  • the range of indications for biodegradable osteosynthesis materials per se is limited to low-stress, rapidly healing fractures. Such fractures can occur, for example, on the • skull (skull, cheekbones or upper jaw).
  • the increase in the stability of the bone and the decrease in the stability of the implant are two dynamically running processes which are expressed in two oppositely running sigmoid curves.
  • the curves overlap in such a way that the stability of the implant decreases to the same extent as the stability of the bone increases again.
  • Figure la) shows the hypothetical course of fracture healing using only a biodegradable osteosynthesis implant, as is the case, for example, in the treatment of the fractures described above Area of the skull occurs. That .
  • the implant must be able to take over the full mechanical load at time 0 and the loss of mechanical stability (minus a certain mechanical stability reserve) may only proceed so quickly that it can be compensated for by increasing the stability of the healing bone tissue.
  • the loss of stability of the implant cannot be equated with the degradation or loss of mass thereof. Due to various physical and chemical processes (e.g. swelling) the implant loses mechanical stability much faster than it loses mass due to abrasion and degradation.
  • an implant not only has to fix the bone fragments during fracture healing, but also has to bear the high mechanical forces acting on the bone.
  • the implant can be largely freed from the latter task by external support or stabilization by means of plaster, splint or external fixator, and it only has to ensure that the fragments are fixed. This significantly extends the range of indications for biodegradable polymer implants.
  • the biodegradable and resorbable implant only has to fix the bone fragments in a certain relative position to one another until the bone material newly formed between them can take over this function again and the additional fixation becomes unnecessary.
  • the mechanical loads that act on the broken bones are borne by the external stabilization until the healing bone has such a high percentage of its mechanical properties has regained that no additional stabilization is necessary. This does not mean that the bone must have regained its full mechanical strength when the external stabilization is removed.
  • Common to all methods is that the affected area is immobilized for a long time and that the reduced muscle activity leads to muscle loss and a deterioration in mobility. To achieve this again, time and cost-intensive therapies must be carried out after removing the external stabilizing agents.
  • PHA Polylactide
  • PGA polyglycolide
  • PCL poly ( ⁇ -caprolactone)
  • PLB poly (ß-hydroxybutyrate)
  • PDS poly (p-dioxanone)
  • Polylactide (PLA) and polyglycolide (PGA) and their copolymers are broken down by hydrolysis. Since the amorphous areas of partially crystalline PLA degrade faster than the crystalline areas, disintegration of the implant in the surrounding tissue can lead to irritation and inflammation (see also E. Wintermantel and SW. Ha, Biocompatible Materials and Construction, Springer Verlag , Berlin, 1996).
  • a second cause of complications can be the acidic hydrolysis products of the implant.
  • the acidic degradation products are removed from the inside of the implant only much more slowly than from their surface, which leads to an accumulation of acidic degradation products and an increasing acceleration of the degradation by the autocatalytically active carboxyl groups. If the remaining outer wall of the implant breaks at a later point in time of the dismantling, the acidic products can be released suddenly and thus lead to a there is a sudden drop in pH in the surrounding tissue, which can also lead to inflammatory reactions.
  • GFs growth factors
  • Soluble low molecular weight proteins such as insulin-like growth factors (IGFs) have long been known for their local effects on the growth of cartilage and bone (Canalis, E. and LG Raisz, Endocr. Rev. 4: 62-77, 1983) known. The same authors demonstrated a positive effect of IGF on bone DNA synthesis in periosteal and non-periosteal bone.
  • IGFs insulin-like growth factors
  • IGF in wound and fracture treatment
  • IGF-1 insulin-like growth factors
  • Somatomedin C is a basic polypeptide consisting of 70 amino acids and has a molecular weight of 7649 D.
  • IGF-1 stimulates inter alia the incorporation of proteoglycan into cartilage by chondrocytes (Froger-Graillard et al., Endocrinology 124: 2365-2372, 1989) and also the synthesis of DNA, RNA and proteins.
  • the slightly acidic polypeptide IGF-2 consists like IGF-
  • IGF 2 consists of 67 amino acids. IGFs are primarily dependent on growth hormone (somatotropin; GH). IGF-1 is predominantly active in adults, while IGF-2 is the main growth factor in the fetus.
  • somatotropin somatotropin
  • TGFs Transforming Growth Factors
  • Bone Morphogenetic Protein BMP
  • BMP Bone Morphogenetic Protein
  • hOP-1 human osteogenetic protein-1
  • BMP-2a recombinant human osteogenetic protein-1
  • DL Griffith et al. Proc. Natl. Acad. Sci. Biophysics 93 (2): 878-883, 1996) describe the three-dimensional structure of osteogenic protein 1 (OP1; BMP-7), which can induce bone formation in vivo.
  • the BMP-4 and BMP-7 are available as recombinant proteins from the BMPs which are members of the TGF beta superfamily.
  • Purified recombinant BMPs appear to be able to induce osteogenesis in vivo only if they are bound to suitable carriers or carriers (E. Tsuruga et al., J. Biochem. 121: 317-324, 1997).
  • Clinetics is currently testing the use of recombinant human BMP-2 (rhBMP-2) and suitable carrier materials to accelerate and ensure the healing of bone fractures and bone defects by the company Genetics Institute®. Similar to the collagen described in EP-A 0 206 801, instead of the body's own bone material (“auto graft”), the carrier materials are intended to serve as placeholders and scaffolds for the newly forming bone tissue. That in EP-A 0 206 801 Stressed collagen has a very good tissue affinity and acts as a carrier material for BMP. However, these collagen preparations only act as a carrier for the growth factors and do not serve to stabilize the fracture or to fix the bone fragments. The object of the present invention is to combine the positive clinical aspects of bioresorbable implants with those of the growth factors and to minimize the possible negative effects of bioresorbable implants.
  • the growth factors (GF) that can be used in the present invention come from the group of epidermal growth factors (EGF) or insulin-like growth factors (IGF) or transforming growth factors beta (TGF-beta) or fibroblast growth factors (FGF). Suitable combinations of two or more of them can of course also be used. Many of the above growth factors are commercially available as lyophilized powders. To produce the implants according to the invention, they are converted into one of the following formulations:
  • the GF is to be introduced into larger polymer bodies, this can be done by adding the GF to the polymer material before or during the extrusion process in the production of bars or band-shaped extrudates at low temperatures or subsequently using the method described by H. Zia et al. 1996 in “Encapsulation and Controlled Release” Thomas Graham House, Cambridge p. 117-130 be accomplished.
  • a GF-containing film layer made of polymer material This can be done either by immersing the implant in a polymer GF solution or by coating or wrapping the implant with prefabricated polymer GF film.
  • Placement in cavities or recesses of the implants is particularly suitable for the microscopic or macroscopic polymer-GF mixtures or the GF gels.
  • the lumen of a banjo bolt can be filled with a positive-locking polymer GF rod after it has been screwed into the bone.
  • the implants produced in this way can have all the configuration forms customary for osteosynthesis implants.
  • Advantageous forms are plates, bandages, fabrics or other flat or rod-shaped elements.
  • connecting elements in the form of screws, rivets, pins, nails, razor wires or cerclages are produced by the methods described above.
  • growth factors that are introduced directly into the fracture area can interact with the implant.
  • the growth factors present in one of the above-mentioned formulations a) to f) are brought into an injectable form and are injected directly into the fracture area or in its immediate vicinity.
  • the biodegradable implant can be spatially separated from the growth factors.
  • the implant is free of growth factors and the growth factors are only available in the injectable formulation.
  • the growth factors injected directly into the • fracture area or in its immediate vicinity interact in an analogous manner to the implants described above with the growth factor-free biodegradable osteosynthesis implant.
  • FIG. 2a shows the healing process of a fracture using an implant according to the invention and the associated growth factors.
  • the solid line shows the accelerated temporal course of new bone formation, respectively the increase in the mechanical strength of the healing bone.
  • the slower increase without using growth factors is shown with the dashed line.
  • the implant must still be able to take on the full mechanical load at time 0, but since it only has to bear this for a much shorter period of time, it can be made from materials that are more quickly degradable.
  • the reduced presence of the implant in the body also transforms the amorphous Polymer material reduced to crystallites, which in turn leads to better tissue compatibility.
  • FIG. 2 b shows the use of an implant according to the invention with growth factors with additional external stabilization of the fracture. This shows the greatest advantage of the present invention.
  • the accelerated bone healing here results in a substantial reduction ( ⁇ t) in the time that the external stabilizing agents have to be worn.
  • ⁇ t substantial reduction
  • the earlier healing of the fracture and the earlier resumption of movement of the affected area not only significantly reduce the duration of the illness, but also significantly reduce the time and financial expenditure required for aftercare.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un implant d'ostéosynthèse pour la liaison mécanique de zones de fracture en un matériau polymère biodégradable, utilisable en ostéosynthèse reconstructive. Une matière active promouvant la régénération des tissus osseux dans la zone de la fracture agit conjointement avec l'implant de manière à promouvoir la croissance dans ladite zone, de façon que la capacité mécanique de charge de la fracture guérie augmente plus rapidement ou, au moins, aussi rapidement que la capacité de charge de l'implant dégradé décroît.
EP98910571A 1997-04-16 1998-04-08 Implant biodegradable d'osteosynthese Withdrawn EP0980273A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH88497 1997-04-16
CH88497 1997-04-16
CH78098 1998-04-01
CH78098 1998-04-01
PCT/CH1998/000133 WO1998046289A1 (fr) 1997-04-16 1998-04-08 Implant biodegradable d'osteosynthese

Publications (1)

Publication Number Publication Date
EP0980273A1 true EP0980273A1 (fr) 2000-02-23

Family

ID=25685667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910571A Withdrawn EP0980273A1 (fr) 1997-04-16 1998-04-08 Implant biodegradable d'osteosynthese

Country Status (5)

Country Link
US (1) US6214008B1 (fr)
EP (1) EP0980273A1 (fr)
JP (1) JP2001519818A (fr)
AU (1) AU6493598A (fr)
WO (1) WO1998046289A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4356299A (en) * 1998-06-29 2000-01-17 White Spot Ag Utilization of growth factors for the production of medicaments
AU2001279073B2 (en) * 2000-07-28 2006-08-24 Christopher J. Murphy Transplant media
EP1420718A4 (fr) * 2000-09-29 2005-12-28 Endovasc Ltd Inc Prosthese resorbable destinee au traitement medical
US7709029B2 (en) * 2001-01-24 2010-05-04 Ada Foundation Calcium-containing restoration materials
US7294187B2 (en) * 2001-01-24 2007-11-13 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US6793725B2 (en) 2001-01-24 2004-09-21 Ada Foundation Premixed calcium phosphate cement pastes
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
JP4510384B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
US6955716B2 (en) 2002-03-01 2005-10-18 American Dental Association Foundation Self-hardening calcium phosphate materials with high resistance to fracture, controlled strength histories and tailored macropore formation rates
KR100496353B1 (ko) * 2002-04-15 2005-06-20 서울산업대학교 산학협력단 약물방출 능을 가진 생분해성 고분자를 이용한 조직공학용생분해성 고분자 지지체 및 그의 제조 방법
JP4824549B2 (ja) * 2003-05-02 2011-11-30 サーモディクス，インコーポレイティド 制御放出型の生体活性物質デリバリー・デバイス
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US20050090828A1 (en) * 2003-08-04 2005-04-28 Alford J. W. Orthopedic hole filler
US7699879B2 (en) * 2003-10-21 2010-04-20 Warsaw Orthopedic, Inc. Apparatus and method for providing dynamizable translations to orthopedic implants
US20050085814A1 (en) * 2003-10-21 2005-04-21 Sherman Michael C. Dynamizable orthopedic implants and their use in treating bone defects
US20050136764A1 (en) * 2003-12-18 2005-06-23 Sherman Michael C. Designed composite degradation for spinal implants
US7942913B2 (en) * 2004-04-08 2011-05-17 Ebi, Llc Bone fixation device
WO2006002366A2 (fr) * 2004-06-24 2006-01-05 Surmodics, Inc. Dispositifs oculaires biodegradables, procedes et systemes associes
US20060034891A1 (en) * 2004-08-12 2006-02-16 Laurie Lawin Biodegradable controlled release bioactive agent delivery device
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7527640B2 (en) * 2004-12-22 2009-05-05 Ebi, Llc Bone fixation system
US7955364B2 (en) * 2005-09-21 2011-06-07 Ebi, Llc Variable angle bone fixation assembly
US20070255422A1 (en) * 2006-04-25 2007-11-01 Mei Wei Calcium phosphate polymer composite and method
DE102006060958A1 (de) 2006-12-20 2008-06-26 Jennissen, Herbert P., Prof. Dr. Verfahren zur Herstellung einer Polymermatrix, daraus bestehende Implantate sowie deren Verwendung
US8870871B2 (en) 2007-01-17 2014-10-28 University Of Massachusetts Lowell Biodegradable bone plates and bonding systems
EP2129517A4 (fr) * 2007-03-26 2012-11-21 Univ Connecticut Charpentes nanocomposites de polymères d'apatite électrofilées
US20100121285A1 (en) * 2007-05-07 2010-05-13 Illi Oskar E Means for the application of active substances in the ear canal of a patient
EP2475316B8 (fr) 2009-09-10 2016-07-13 Woodwelding AG Dispositif à implanter dans l'organisme de l'homme ou de l'animal pour l'administration de signaux dans l'organisme
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655777A (en) * 1983-12-19 1987-04-07 Southern Research Institute Method of producing biodegradable prosthesis and products therefrom
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
FI81498C (fi) * 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5470829A (en) 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
FR2689400B1 (fr) * 1992-04-03 1995-06-23 Inoteb Materiau pour prothese osseuse contenant des particules de carbonate de calcium dispersees dans une matrice polymere bioresorbable.
ATE164304T1 (de) * 1992-04-28 1998-04-15 Donald R Huene Absorbierbare knochenschraube und werkzeug zum einsetzen derselben
US5522841A (en) * 1993-05-27 1996-06-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5522895A (en) * 1993-07-23 1996-06-04 Rice University Biodegradable bone templates
AU2952195A (en) * 1994-06-28 1996-01-25 Board Of Regents, The University Of Texas System Biodegradable fracture fixation plates and uses thereof
WO1996034634A1 (fr) * 1995-05-01 1996-11-07 Sam Yang Co. Ltd. Membrane bioresorbable implantable et son procede de preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9846289A1 *

Also Published As

Publication number Publication date
WO1998046289A1 (fr) 1998-10-22
US6214008B1 (en) 2001-04-10
JP2001519818A (ja) 2001-10-23
AU6493598A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
EP0980273A1 (fr) Implant biodegradable d'osteosynthese
DE69118535T2 (de) Osteo-induktive pharmazeutische formulierungen
DE69432596T2 (de) Zusammensetzungen für verabreichung von osteogenen proteinen
JP4414218B2 (ja) 骨誘導性タンパク質のためのリン酸カルシウム送達ビヒクル
Bax et al. Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia
DE69738398T2 (de) Biokeramische zusammensetzung
CN108135702B (zh) 具有氧化固醇药物负载的植入物和使用方法
EP2094323B1 (fr) Traitement de l'ostéoporose
US10363238B2 (en) Methods and compositions to enhance bone growth comprising a statin
DE602004005477T2 (de) Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
DE69915881T2 (de) Sequenzierte inkorporation von kortikalknochentransplantaten
JP2007533376A (ja) 遅延凝固リン酸カルシウムペースト
DE60016614T2 (de) Zusammensetzungen zur abgabe osteogener proteine
US8673019B2 (en) Use of anti-inflammatory compounds with allograft tissue implantation
CN108392680B (zh) 一种可塑形全降解硬组织填充生物材料
EP0885617A2 (fr) Matériau pour implant muni d'une combinaison support-produit actif
IIIi et al. Stimulation of fracture healing by local application of humoral factors integrated in biodegradable implants
WO1996000592A2 (fr) Plaques de fixation biodegradables pour fractures et leurs utilisations
Blokhuis Formulations and delivery vehicles for bone morphogenetic proteins: latest advances and future directions
EP2214733B1 (fr) Matériau composite biologique pour la libération contrôlée d'agents actifs
EP1091730A1 (fr) Utilisation de facteurs de croissance pour la production d'un medicament
AU2008247320B2 (en) A method for treating inflammation and controlled-release material capable of providing same
EP2104520B1 (fr) Procede de fabrication d'un produit comportant une matrice polymere, des implants issus de celle-ci ainsi que son utilisation
DE10305810A1 (de) Knochenfüllmaterial
Gradinger et al. Bioaktive Oberflächenbeschichtung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990909

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 20030210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030821